Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TP53-EphA-2-CAR-DC
i
Other names:
TP53-EphA-2-CAR-DC, autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Chinese PLA General Hospital
Drug class:
Dendritic cell activator, EphA2 inhibitor
Related drugs:
‹
PVS-RIPO (1)
GEN-001 (0)
HER-2 pulsed DC1 (0)
ID-LV305 (0)
IMM-101 (0)
ilixadencel (0)
KRAS-EphA-2-CAR-DC (0)
CDX-301 (0)
NC410 (0)
ORB-011 (0)
LOAd703 (0)
DC-TC (0)
CDX-1401 (0)
personalized cellular vaccine (0)
PVS-RIPO (1)
GEN-001 (0)
HER-2 pulsed DC1 (0)
ID-LV305 (0)
IMM-101 (0)
ilixadencel (0)
KRAS-EphA-2-CAR-DC (0)
CDX-301 (0)
NC410 (0)
ORB-011 (0)
LOAd703 (0)
DC-TC (0)
CDX-1401 (0)
personalized cellular vaccine (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors (NCT05631886)
Phase 1
Chinese PLA General Hospital
Chinese PLA General Hospital
Recruiting
Phase 1
Chinese PLA General Hospital
Recruiting
Last update posted :
08/28/2023
Initiation :
07/04/2023
Primary completion :
12/30/2025
Completion :
12/30/2026
TP53 • IL6 • IL2 • IL10
|
PD-L1 expression • TP53 mutation • MSI-H/dMMR • TP53 R175H • TP53 R248Q • TP53 R273H
|
Yervoy (ipilimumab) • albumin-bound paclitaxel • cyclophosphamide • TP53-EphA-2-CAR-DC
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login